Astrazeneca plc (AZN)
Income statement / Quarterly
Jun'18Jun'17
Product Sales

5,030

4,940

Externalisation Revenue

125

111

Total Revenue

5,155

5,051

Cost of sales

1,012

950

Gross profit

4,143

4,101

Distribution costs

84

72

Research and development expense

1,362

1,349

Selling, general and administrative costs

2,551

2,358

Other operating income & expense

617

603

Operating profit

763

925

Finance income

43

28

Finance expense

375

448

Share of after tax losses in associates and joint ventures

-19

-13

Profit before tax

412

492

Taxation

93

46

Profit for the period

319

446

Other comprehensive income:
Remeasurement of the defined benefit pension liability

160

-272

Fair value movements on equity investments

38

-

Fair value movements related to own credit risk on bonds designated as fair value through profit or loss

-1

-

Tax on items that will not be reclassified to profit or loss

40

-72

Total other comprehensive income that will not be reclassified to profit or loss, net of tax

157

-200

Foreign exchange arising on consolidation

-451

223

Foreign exchange arising on designating borrowings in net investment hedges

-417

283

Fair value movements on cash flow hedges

-117

120

Fair value movements on cash flow hedges transferred to profit or loss

-149

161

Fair value movements on derivatives designated in net investment hedges

44

-5

Amortisation of loss on cash flow hedge

0

-1

Fair value movements on equity investments

0

56

Tax on items that may be reclassified subsequently to profit or loss

-35

94

Total other comprehensive income that will be reclassified to profit or loss, net of tax

-757

423

Other comprehensive (loss) / income for the period, net of tax

-600

223

Total comprehensive income for the period

-281

669

Owners of the Parent

350

477

Non-controlling interests

-31

-31

Total comprehensive income attributable to:
Owners of the Parent

-250

700

Non-controlling interests

-31

-31

Total comprehensive income for the period

-281

669

Basic earnings loss per (in dollars per share)

0.27

0.38

Diluted earnings loss per Share (in dollars per share)

0.27

0.38

Weighted average number of Ordinary Shares in issue for basic earnings

1,267

1,266

Diluted weighted average number of Ordinary Shares in issue (millions)

1,267

1,267